

## Special Issue

# New Advancements in Chronic Inflammatory Skin Disease

### Message from the Guest Editors

Chronic inflammatory skin diseases represent a great proportion of skin diseases, and the therapy in daily life is challenging. Most of these diseases (e.g., psoriasis, atopic dermatitis, hidradenitis suppurativa) are characterized by undertreatment and/or a great delay in correct diagnosis and proper treatment. Therefore, the quality of life of these patients is very poor. In recent years, many new biologics and small molecules have been introduced for the treatment of chronic inflammatory skin diseases, substantially changing the clinical profile of patients and in some cases avoiding the progression of the underlying disease. In some instances, to the great success of the clinical outcomes the quality of life has also improved as a consequence. On the other hand, as is the case with hidradenitis suppurativa, not all these efforts in research and development resulted in effective therapies. Understanding triggers may be crucial to increasing therapeutic effectiveness and preventing the exacerbation of these chronic conditions.

---

### Guest Editors

Prof. Dr. Francesca Prignano

Dr. Antonella Di Cesare

Dr. Elia Rosi

---

### Deadline for manuscript submissions

closed (31 August 2022)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/105839](https://mdpi.com/si/105839)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).